HIMS 📈 Hims Hers Health - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4330001060
HIMS: Prescription Medication, Skincare, Haircare, Sexual Wellness, Supplements
Hims & Hers Health, Inc. is a telehealth company that facilitates connections between consumers and licensed healthcare professionals across the United States, the United Kingdom, and other international markets. The platform provides access to a wide range of health and wellness products, including prescription and non-prescription items, which can be purchased directly through their website or mobile application. This approach enables customers to take a more proactive and convenient approach to managing their health and wellness.
The company's product portfolio is diverse, encompassing prescription medications that can be dispensed on a recurring basis, as well as ongoing care services from healthcare providers. Additionally, they offer a variety of over-the-counter products, including drugs, devices, cosmetics, and supplements, with a focus on general wellness, sexual health, skincare, and hair care. For instance, their wellness products include melatonin and biotin, while their skincare line features moisturizers, creams, sunscreen, and face wash. They also cater to sexual health and wellness with products like condoms, climax delay sprays, and lubricants, and their hair care range includes shampoos, conditioners, and scalp treatments.
Furthermore, Hims & Hers Health, Inc. provides medical consultation services, offering customers the opportunity to consult with healthcare professionals and receive post-consultation support. The company also partners with wholesale providers to offer its health and wellness products, expanding its reach and accessibility. As a San Francisco, California-based company, Hims & Hers Health, Inc. operates with a strong online presence, including its website at https://www.forhims.com, and is listed on the New York Stock Exchange (NYSE) under the ticker symbol HIMS, with the ISIN US4330001060, classified as a common stock in the Health Care Services sub-industry.
Additional Sources for HIMS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HIMS Stock Overview
Market Cap in USD | 6,827m |
Sector | Consumer Defensive |
Industry | Household & Personal Products |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2019-09-13 |
HIMS Stock Ratings
Growth 5y | 50.2% |
Fundamental | 78.9% |
Dividend | - |
Rel. Strength Industry | 4062 |
Analysts | 3.42/5 |
Fair Price Momentum | 25.94 USD |
Fair Price DCF | 19.74 USD |
HIMS Dividends
No Dividends PaidHIMS Growth Ratios
Growth Correlation 3m | 85.9% |
Growth Correlation 12m | 81.7% |
Growth Correlation 5y | 11.1% |
CAGR 5y | 21.92% |
CAGR/Mean DD 5y | 0.46 |
Sharpe Ratio 12m | 1.62 |
Alpha | 178.97 |
Beta | 1.00 |
Volatility | 107.27% |
Current Volume | 17296.3k |
Average Volume 20d | 16748.2k |
As of December 22, 2024, the stock is trading at USD 26.20 with a total of 17,296,326 shares traded.
Over the past week, the price has changed by -12.72%, over one month by +20.24%, over three months by +60.74% and over the past year by +214.15%.
Yes, based on ValueRay Fundamental Analyses, Hims Hers Health (NYSE:HIMS) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 78.94 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HIMS as of December 2024 is 25.94. This means that HIMS is currently overvalued and has a potential downside of -0.99%.
Hims Hers Health has received a consensus analysts rating of 3.42. Therefor, it is recommend to hold HIMS.
- Strong Buy: 2
- Buy: 2
- Hold: 7
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, HIMS Hims Hers Health will be worth about 28.8 in December 2025. The stock is currently trading at 26.20. This means that the stock has a potential upside of +10.08%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 24.9 | -5% |
Analysts Target Price | 12.3 | -53.1% |
ValueRay Target Price | 28.8 | 10.1% |